// App-Quantinova.ai

P248 : Subcutaneous secukinumab 150 mg provides rapid and sustained relief in total and nocturnal back pain, morning stiffness and fatigue in patients with active AS over 4 years

Researchers

Presenter

  • Helena Marzo-Ortega

Principal Investigators

  • Corinne Miceli-Richard

  • Sonja Gill

  • Marina Magery

  • Paula G. P Machado

  • Abhijit Shete

  • Jianyuan Wang

  • Susanne Rohrer

  • Atul Deodhar

Medical Centers

  • National Institute for Health Research Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust, University of Leeds, Leeds, UNITED KINGDOM

  • Department of Rheumatology - Hôpital Cochin, Paris Descartes University, Assistance Publique - Hôpitaux de Paris, Paris, FRANCE

  • – 3075 Hospital Gate, Oakville, Ontario, ON, CANADA

  • School of Medicine, Case Western Reserve University, Cleveland, OH

  • Novartis Pharmaceutical Corporation, East Hanover, NJ

  • Immunology, Hepatology, and Dermatology Development Unit, Novartis Pharma AG, Basel, SWITZERLAND

  • Division of Arthritis & Rheumatic Diseases, Oregon Health & Science University, Portland, OR

Locations

  • United Kingdom

  • France

  • Canada

  • United States

  • Switzerland

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • Tumor necrosis factor

Drug/Treatment

  • secukinumab

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved